← Research
Sep 2023 Phase 3
MDMA-Assisted Therapy for Moderate to Severe PTSD: A Randomized, Placebo-Controlled Phase 3 Trial
Mitchell JM, Ot'alora G. M, van der Kolk B, et al. — University of California, San Francisco / MAPS
Published in Nature Medicine
MDMA PTSD
The confirmatory "MAPP2" Phase 3 trial — 104 patients with moderate-to-severe PTSD, broader and more diverse than the first Phase 3 study. Met both primary and secondary endpoints, confirming the earlier 2021 trial's results; safety profile was consistent with prior MDMA-assisted therapy studies.
Read the Full Paper at Nature Medicine